Public Research Library
Specialties:
Most Popular Reports:
- Laser Body Sculpting SmartLipo-Trends in Use
- Essure Permanent Birth Control
- Oral Contraceptives Market Evaluation
- Trends and Forecast of Dental Implant Cases
- Avastin and the AVADO Trial Survey
Newest Reports:
Pulmonary Arterial Hypertension: Market Outlook
A Survey of 38 Pulmonologists
Deliverable: Survey in PowerPoint with key findings.
Study Description:
|
Topic |
Pulmonary Arterial Hypertension |
|
Respondent Type |
Physicians |
|
Specialties Covered |
Pulmonology |
|
Region |
United States Only |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website § Approximately 30 minutes duration § 38 total respondents § Fielded online from November 7, 2007 to November 14, 2007 |
Objectives:
To understand current practices and trends regarding the use of endothelin receptor agonists (ETRA’s) in patients with pulmonary arterial hypertension (PAH) and the impact to market of newly publicized data from the TRIUMPH trial. Secondary objectives include:
§ Determine current practice patterns in PAH.
§ Quantify usage of ETRA’s and practice usage in PAH patients.
§ Identify drivers of ETRA brand preference and forecast prescribing patterns.
§ Examine current practice methods for monitoring therapy.
§ Predict the impact that inhaled prostacyclin therapy will have on the PAH market as it relates to prescribing patterns and patient monitoring.
§ Determine the effectiveness of Gilead’s commercial organization for launching Letairis.
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Actelion Pharmaceuticals US, Inc. |
ACT.DE |
Tracleer |
|
Gilead |
GILD |
Letairis |
Inclusion Criteria and Respondent Demographics:
|
Inclusion Criteria
|
§ US-based pulmonologists § Board-certified in specialty § 2 to 30 years of experience post-residency § Minimum of 75% professional time spent in clinical practice § Treating at least 40 PAH patients § Have initiated at least 2 patients on Letairis therapy |
Reports become free one year after the publication date.
 about us contact us |
 |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |